Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Ra Capital Management, L.P. Acquires 320,913 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Ra Capital Management, L.P. acquired 320,913 shares of Werewolf Therapeutics stock in a transaction dated Monday, May 12th. The shares were acquired at an average price of $0.86 per share, with a total value of $275,985.18. Following the transaction, the director now owns 6,021,969 shares in the company, valued at approximately $5,178,893.34. This represents a 5.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, May 14th, Ra Capital Management, L.P. bought 162,539 shares of Werewolf Therapeutics stock. The stock was acquired at an average price of $0.98 per share, for a total transaction of $159,288.22.

Werewolf Therapeutics Trading Down 2.9%

Shares of HOWL opened at $0.99 on Thursday. The business’s 50-day moving average price is $0.93 and its 200 day moving average price is $1.40. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $44.43 million, a P/E ratio of -0.65 and a beta of 0.48. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $5.73.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, May 8th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.04. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. Analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Werewolf Therapeutics by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock valued at $1,040,000 after purchasing an additional 16,569 shares in the last quarter. Northern Trust Corp raised its position in Werewolf Therapeutics by 7.3% during the fourth quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock valued at $362,000 after buying an additional 16,640 shares during the period. Bridgeway Capital Management LLC lifted its stake in Werewolf Therapeutics by 24.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company’s stock worth $162,000 after acquiring an additional 21,500 shares in the last quarter. Deutsche Bank AG lifted its stake in Werewolf Therapeutics by 450.7% in the 4th quarter. Deutsche Bank AG now owns 101,626 shares of the company’s stock worth $150,000 after acquiring an additional 83,172 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after acquiring an additional 23,852 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on HOWL shares. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a report on Wednesday, March 12th. Wedbush reduced their price objective on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a research note on Friday, May 9th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.